Alaunos Therapeutics (TCRT) Common Equity (2009 - 2026)

Alaunos Therapeutics has reported Common Equity for 18 years, with the latest figure at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 21.74% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (up 21.74% YoY), and the FY2025 full-year result was $2.2 million, up 4.36% from the prior year.
• Common Equity for Q1 2026 stood at $1.3 million, down from $2.2 million in the prior quarter.
• The five-year high for Common Equity was $49.1 million in Q1 2022, with the low at $1.1 million in Q1 2025.
• Historically, Common Equity has averaged $15.0 million across 5 years, with a median of $4.8 million in 2024.
• Annual changes were most pronounced in 2024 — Common Equity plunged 83.74% — and 2026, when it advanced 21.74%.
• Alaunos Therapeutics' Common Equity stood at $38.6 million in 2022, then sank by 83.64% to $6.3 million in 2023, then plunged by 67.29% to $2.1 million in 2024, then advanced by 4.36% to $2.2 million in 2025, then plunged by 40.18% to $1.3 million in 2026.
• The last three Common Equity figures came in at $1.3 million (Q1 2026), $2.2 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.